On October 5th, we hosted an expert call discussion on how the ECLIPSE results and potential introduction of liquid biopsy might influence the market for CRC screening. Topics of discussion included adoption of non-invasive diagnostics for colorectal cancer screening, such as Cologuard and liquid biopsy. In addition, we will discuss the how emerging entrants in liquid biopsy stack up in the testing paradigm.